Immunohistochemical markers of prognostic value in surgical pathology

Histology and Histopathology

Volumn 12, Issue 4, 1997, Pages 1039-1055

  Taylor, C R ^a   Cote, R J ^a  

^a Department of Pathology and Laboratory Medicine ^*  (United States)

Author keywords

Immunohistochemistry; Micrometastases; Oncogenes; Prognostic markers; Proliferation markers; Tumor suppressor genes

Indexed keywords

BONE MARROW; CANCER INVASION; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; IMMUNOHISTOCHEMISTRY; LYMPHOMA; METASTASIS; OCCULT CANCER; ONCOGENE; PROGNOSIS; REVIEW; TUMOR SUPPRESSOR GENE;

ANIMALS; BIOLOGICAL MARKERS; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; PROGNOSIS;

EID: 0030765582     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (12)

1. Allred D.C., Bustamante M.A., Daniel C.O., Gaskill H.V. and Cruz A.B. Jr. (1990). Immunocytochemical analysis of estrogen receptors in human breast carcinomas. Evaluation of 130 cases and review of the literature regarding concordance with biochemical assay and clinical relevance. Arch. Surg. 125, 107-113.
2. Allred D.C., Clark G.M., Tandon A.K., Molina R., Tormey D.C., Osborne C.K., Gilchrist K.W., Mansour E.G., Abeloff M. and Eudey. L. (1992). HER-2/neu in node-negative breast cancer, prognostic significance of overexpression influenced by the presence of in situ carcinoma. J. Clin. Oncol. 10, 599-605.
3. Beatson G.T. (1986). On the treatment of inoperable cases of carcinoma of the mamma, suggestions for a new method of treatment, with illustrative cases. Lancet 2, 104-107-162-165.
4. Birembaut P., Caron Y. and Adnet J.J. (1985). Usefulness of basement membrane markers in tumoral pathology. J. Pathol. 145, 283-296.
5. Borg A., Zhang Q-X., Alm P., Olsson H. and Sellberg G. (1992). The retinoblastoma gene in breast cancer, allele loss is not correlated with loss of gene protein expression. Cancer Res. 52, 2991-2994.
6. Bretton P.R., Melamed M.R., Fair W.R. and Cote R.J. (1994). Detection of occult micrometastases in the bone marrow of patients with prostate carcinoma. Prostate 25, 108-114.
7. Carpenter G. and Cohen S. (1979). Epidermal growth factor. Annu. Rev. Biochem. 48, 193-216.
8. Walker R.A., Dearing S.J., Lane D.P. and Varley J.M. (1991). Expression of p53 protein in infiltrating and in situ breast carcinomas. J. Pathol. 165, 203-211.
9. Wick M.R. (1989) Immunohistologic detection of ras oncogene products., Specific or spurious? Arch. Pathol. Lab. Med. 113, 13-15.
10. Wick M.R., Lillemoe T.J., Copland G.T., Swanson P.E., Manivel J.C. and Kiang D.T. (1989). Gross cystic disease fluid protein-15 as a marker for breast cancer, immunohistochemical analysis of 690 human neoplasms and comparison with alpha-lactalbumin. Hum. Pathol. 20, 281-287.
11. Xu H-J., Hu S-X., Cagle P-T., Moore G.E. and Benedict W.F. (1991). Absence of retinoblastoma protein expression in primary non- small cell lung carcinomas. Cancer. Res. 51, 2735-2739.
12. Yang G.-Y., and Shasuddin A.H. (1996). Gal-GalNAc: a biomarker of colon carcinogenesis. Histol. Histopathol. 11, 801-806.